Based on the key indicators related to CAMP4 THERAPEUTICS's liquidity, profitability, solvency, and operating efficiency, CAMP4 THERAPEUTICS PORATION may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At this time, CAMP4 THERAPEUTICS's Intangible Assets are relatively stable compared to the past year. Key indicators impacting CAMP4 THERAPEUTICS's financial strength include:
Investors should never underestimate CAMP4 THERAPEUTICS's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor CAMP4 THERAPEUTICS's cash flow, debt, and profitability to make informed and accurate decisions about investing in CAMP4 THERAPEUTICS PORATION.
Net Income
(79.74 Million)
CAMP4
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Capex To Depreciation
Pb Ratio
Roic
Inventory Turnover
Net Income Per Share
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Current Ratio
Receivables Turnover
Debt To Equity
Revenue Per Share
Debt To Assets
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Ev To Sales
Free Cash Flow Per Share
Days Of Inventory On Hand
Capex To Revenue
Cash Per Share
Days Payables Outstanding
Net Debt To E B I T D A
Tangible Book Value Per Share
Shareholders Equity Per Share
Capex Per Share
Graham Net Net
Interest Debt Per Share
Enterprise Value Over E B I T D A
Graham Number
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Operating Cycle
Days Of Payables Outstanding
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Enterprise Value Multiple
Change To Inventory
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Other Cashflows From Investing Activities
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Current Deferred Revenue
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Net Receivables
Good Will
Liabilities And Stockholders Equity
Non Current Liabilities Total
Inventory
Other Current Assets
Other Stockholder Equity
Total Liab
Total Current Assets
Accumulated Other Comprehensive Income
Short Term Debt
Intangible Assets
Common Stock
Common Stock Shares Outstanding
Depreciation And Amortization
Interest Expense
Selling General Administrative
Selling And Marketing Expenses
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Probability Of Bankruptcy
Understanding current and past CAMP4 THERAPEUTICS Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of CAMP4 THERAPEUTICS's financial statements are interrelated, with each one affecting the others. For example, an increase in CAMP4 THERAPEUTICS's assets may result in an increase in income on the income statement.
CAMP4 THERAPEUTICS competes with Harmonic, CommScope Holding, NETGEAR, Comtech Telecommunicatio, and Knowles Cor. CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company was incorporated in 1981 and is headquartered in Irvine, California. CalAmp Corp operates under Communication Equipment classification in the United States and is traded on NASDAQ Exchange. It employs 887 people.
Comparative valuation techniques use various fundamental indicators to help in determining CAMP4 THERAPEUTICS's current stock value. Our valuation model uses many indicators to compare CAMP4 THERAPEUTICS value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across CAMP4 THERAPEUTICS competition to find correlations between indicators driving CAMP4 THERAPEUTICS's intrinsic value. More Info.
CAMP4 THERAPEUTICS PORATION is rated below average in current valuation category among its peers. It is rated below average in shares outstanding category among its peers creating about 0.18 of Shares Outstanding per Current Valuation. The ratio of Current Valuation to Shares Outstanding for CAMP4 THERAPEUTICS PORATION is roughly 5.44 . As of 03/26/2025, Common Stock Shares Outstanding is likely to drop to about 39.3 M. Comparative valuation analysis is a catch-all technique that is used if you cannot value CAMP4 THERAPEUTICS by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
CAMP4 THERAPEUTICS Systematic Risk
CAMP4 THERAPEUTICS's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. CAMP4 THERAPEUTICS volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on CAMP4 THERAPEUTICS correlated with the market. If Beta is less than 0 CAMP4 THERAPEUTICS generally moves in the opposite direction as compared to the market. If CAMP4 THERAPEUTICS Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one CAMP4 THERAPEUTICS is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of CAMP4 THERAPEUTICS is generally in the same direction as the market. If Beta > 1 CAMP4 THERAPEUTICS moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in CAMP4 THERAPEUTICS Stock are looking for potential investment opportunities by analyzing not only static indicators but also various CAMP4 THERAPEUTICS's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of CAMP4 THERAPEUTICS growth as a starting point in their analysis.
CAMP4 THERAPEUTICS March 26, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of CAMP4 THERAPEUTICS help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of CAMP4 THERAPEUTICS PORATION. We use our internally-developed statistical techniques to arrive at the intrinsic value of CAMP4 THERAPEUTICS PORATION based on widely used predictive technical indicators. In general, we focus on analyzing CAMP4 Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build CAMP4 THERAPEUTICS's daily price indicators and compare them against related drivers.
When running CAMP4 THERAPEUTICS's price analysis, check to measure CAMP4 THERAPEUTICS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CAMP4 THERAPEUTICS is operating at the current time. Most of CAMP4 THERAPEUTICS's value examination focuses on studying past and present price action to predict the probability of CAMP4 THERAPEUTICS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CAMP4 THERAPEUTICS's price. Additionally, you may evaluate how the addition of CAMP4 THERAPEUTICS to your portfolios can decrease your overall portfolio volatility.